SCYNEXIS (SCYX)
NASDAQ:SCYX
Want to see SCYX full AI Analyst Report?
SCYX Stock Chart & Stats
$0.66
-$0.06(-4.73%)
At close: 4:00 PM EST
$0.66
-$0.06(-4.73%)
Day’s Range― - ―
52-Week Range$4.15 - $10.48
Previous CloseN/A
Volume100.07K
Average Volume (3M)612.75K
Market Cap
$41.21M
Enterprise Value$891.29K
Total Cash (Recent Filing)$59.26M
Total Debt (Recent Filing)$2.06M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Aug 17, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.60
Shares Outstanding9,930,329
10 Day Avg. Volume689,890
30 Day Avg. Volume612,753
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.64
Price to Sales (P/S)1.53
P/FCF Ratio-5.98
Enterprise Value/Market Cap0.02
Enterprise Value/Revenue0.04
Enterprise Value/Gross Profit0.04
Enterprise Value/Ebitda-0.04
Forecast
1Y Price Target
$32.00Price Target Upside4748.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.99
Revenue Forecast (FY)$1.17M
Bulls Say, Bears Say
Bulls Say
Pipeline Diversification (ADPKD)Acquiring SCY-770 moves the company beyond antifungals into a high-value orphan nephrology market with an FDA-endorsed surrogate endpoint and IP protection into 2042. This materially diversifies long-term product risk and creates a clear clinical development path (Phase 2 late-2026) that can produce sustainable, higher-margin revenue if successful.
Extended Funding RunwayThe $40M PIPE materially lengthens the company’s cash runway into mid-2029, reducing immediate financing risk and permitting advancement of SCY-770 into Phase 2 plus continued antifungal programs. Backing from specialist healthcare investors and registration rights improves funding optionality to reach value-driving clinical readouts without near-term dilution pressure.
Conservative LeverageRelatively low net debt and conservative leverage provide financial flexibility while the company invests in R&D. This structural balance-sheet strength lowers insolvency risk, supports strategic choices (acquisitions, trials), and complements the PIPE proceeds, making it more feasible to fund development milestones without immediate dependency on high-cost debt or dilutive equity.
Bears Say
Negative Cash FlowPersistent negative operating and free cash flow shows the company is not yet self-funding and remains reliant on financings and partner payments to operate. Even with the PIPE, continued burn through clinical development could force additional dilution or constrain program pacing if expected milestone or partner receipts are delayed or underperform.
Volatile ProfitabilityLarge swings from prior profitability to steep losses reflect reliance on lumpy milestone/licensing revenue and limited durable product cash flows. Deep negative margins reduce reinvestment capacity and increase execution risk: absent consistent product sales or material milestone receipts, earnings durability is weak and sensitive to a small number of outcomes.
Reverse Stock SplitA 1-for-8 reverse split and share-authority reduction signals prior capitalization and listing/float concerns. Structural effects include reduced trading liquidity, higher per-share exercise prices for options/warrants, and potential investor apprehension, which can complicate future equity raises and marketability—relevant if additional funding is needed.
SCYNEXIS News
SCYX FAQ
What was SCYNEXIS’s price range in the past 12 months?
SCYNEXIS lowest stock price was $4.15 and its highest was $10.48 in the past 12 months.
What is SCYNEXIS’s market cap?
SCYNEXIS’s market cap is $41.21M.
When is SCYNEXIS’s upcoming earnings report date?
SCYNEXIS’s upcoming earnings report date is Aug 17, 2026 which is in 67 days.
How were SCYNEXIS’s earnings last quarter?
SCYNEXIS released its earnings results on May 11, 2026. The company reported -$3.36 earnings per share for the quarter, missing the consensus estimate of -$0.987 by -$2.373.
Is SCYNEXIS overvalued?
According to Wall Street analysts SCYNEXIS’s price is currently Undervalued.
Does SCYNEXIS pay dividends?
SCYNEXIS does not currently pay dividends.
What is SCYNEXIS’s EPS estimate?
SCYNEXIS’s EPS estimate is -0.51.
How many shares outstanding does SCYNEXIS have?
SCYNEXIS has 9,930,329 shares outstanding.
What happened to SCYNEXIS’s price movement after its last earnings report?
SCYNEXIS reported an EPS of -$3.36 in its last earnings report, missing expectations of -$0.987. Following the earnings report the stock price went down -5.34%.
Which hedge fund is a major shareholder of SCYNEXIS?
Currently, no hedge funds are holding shares in SCYX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SCYNEXIS Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.00 (4748.48% Upside)
$32.00 (4748.48% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 13.1%
Last 30 Days ▲ 13.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.87%
12-Months-Change
Fundamentals
Return on Equity
-57.16%
Trailing 12-Months
Asset Growth
14.30%
Trailing 12-Months
Company Description
SCYNEXIS
SCYNEXIS, Inc. is a biotechnology firm based in the U.S. dedicated to developing therapies for fungal infections. The company's flagship product, BREXAFEMME (ibrexafungerp tablets), has received approval for the treatment of vulvovaginal candidiasis (VVC). Furthermore, SCYNEXIS is progressing ibrexafungerp, its leading drug candidate, as both an oral and intravenous medicine designed to address various fungal conditions, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and challenging refractory invasive fungal infections. Ibrexafungerp has successfully completed the Phase 3 CANDLE study, which evaluated its effectiveness in preventing recurrent VVC. SCYNEXIS has also established collaborative research and commercialization agreements for ibrexafungerp with partners such as Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC. Founded in 1999, the company is headquartered in Jersey City, New Jersey, and changed its name from SCYNEXIS Chemistry & Automation, Inc. to its current designation in June 2002.
SCYX Stock 12 Month Forecast
Average Price Target
$32.00
▲(4748.48% Upside)
Technical Analysis
Rockwell Med
―
TherapeuticsMD
―
Aytu BioScience
―
Cumberland Pharmaceuticals
―
IM Cannabis Corp
―
Ownership Overview
27.81% Insiders
51.17% Mutual Funds
― Other Institutional Investors
4.39% Public Companies and
Individual Investors